Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$0.22
<$0.01(2.52%)
At close: 4:00 PM EDT
$0.22
<$0.01(2.52%)
Day’s Range― - ―
52-Week Range$0.16 - $4.63
Previous CloseN/A
Volume131.13K
Average Volume (3M)2.66M
Market Cap
$4.52M
Enterprise Value$19.70
Total Cash (Recent Filing)$1.77M
Total Debt (Recent Filing)$12.14M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 18, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding20,118,023
10 Day Avg. Volume2,487,494
30 Day Avg. Volume2,662,481
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.93Price Target Upside775.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$24.06M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross Margin ImprovementStrong top-line growth alongside improving gross margins suggests increasing demand and better economic quality in the business. If sustained, this can provide operating leverage and support a more durable path toward profitability as the company scales its clinical services.
Expanded Henderson Treatment CapacityThe expanded facility increases Vivos’ ability to serve patients, integrate diagnostics with treatment, and capture referrals in one location. Greater capacity and a broader local clinical footprint can support multi-quarter revenue growth if referral momentum and staffing continue.
Strengthened Intellectual Property ProtectionAdditional patent coverage can make the core appliance technology harder to design around and help protect differentiation in severe and pediatric OSA treatment. Stronger IP may support provider adoption, commercial durability, and expansion of the company’s non-CPAP platform.
Bears Say
Persistent Cash Burn And Limited LiquidityThe company is consuming cash faster than operations generate it and has limited funds relative to its needs. Continued reliance on external financing creates execution risk, while funding delays could constrain growth initiatives and threaten business continuity.
Negative Equity And Nasdaq Compliance RiskNegative equity reduces financial flexibility and signals that liabilities exceed the book value of assets. The Nasdaq deficiency adds a structural financing and listing risk, potentially forcing equity issuance, debt conversion, or cost reductions that could dilute owners.
Unprofitable Operations And Product-Mix PressureRevenue growth has not yet translated into sustainable profitability, while the core appliance business is shifting toward lower-priced units. High operating expenses and rising treatment costs may continue to absorb gross profit unless the service mix and scale improve materially.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.16 and its highest was $4.63 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $4.52M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 77 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.1.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 20,118,023 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational progress: solid revenue growth (Q2 +35%, YTD +51%), improving gross margins, tangible contributions from the Sleep Center of Nevada (sleep testing, treatment), and multiple identified recurring-revenue initiatives (remote monitoring, DME CPAP, EEG/insomnia, pediatric program). However, material financial challenges dominate the risk profile — rising operating losses and cost of sales, heavy cash burn ($9.2M YTD), just $1.8M of cash on hand, substantial doubt about the company’s ability to continue as a going concern, and non-compliance with NASDAQ equity requirements that could trigger delisting. Management’s path to cash-flow positivity by late 2026/early 2027 is plausible but highly execution-dependent and contingent on securing additional financing. Given the severity of near-term liquidity and regulatory (NASDAQ) risks despite operational momentum, the negatives weigh heavily.View all VVOS earnings summariesVVOS Stock 12 Month Forecast
Average Price Target
$1.93
▲(775.00% Upside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
7.97% Insiders
1.56% Mutual Funds
0.63% Other Institutional Investors
89.54% Public Companies and
Individual Investors